Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Heron Therapeutics (HRTX) stocks in Canada

Learn how to easily invest in Heron Therapeutics stocks.

Heron Therapeutics (HRTX) is a leading biotechnology business based in the US. It opened the day at $14.17 after a previous close of $14.17. During the day the price has varied from a low of $13.83 to a high of $14.17. The latest price was $14.02 (25 minute delay). Heron Therapeutics is listed on the NASDAQ and employs 223 staff. All prices are listed in US Dollars.

How to buy shares in Heron Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Heron Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Heron Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Heron Therapeutics's stock price has had significant negative movement.

Its last market close was $8.14, which is 62.05% down on its pre-crash value of $21.45 and 17.94% down on the lowest point reached during the March crash when the stocks fell as low as $9.6.

If you had bought $1,000 worth of Heron Therapeutics stocks at the start of February 2020, those stocks would have been worth $522.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $390.80.

Heron Therapeutics stock price (NASDAQ:HRTX)

Use our graph to track the performance of HRTX stocks over time.

Heron Therapeutics shares at a glance

Information last updated 2021-07-09.
Previous close$14.17
Change $-0.15
Change % -1.0586%
Volume 720,917
Information last updated 2022-01-17.
52-week range$8.09 - $20.45
50-day moving average $9.76
200-day moving average $12.54
Wall St. target price$31.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.39

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Heron Therapeutics price performance over time

Historical closes compared with the close of $14.02 from 2022-01-18

1 week (2022-01-10) 63.79%
1 month (2021-12-17) 45.28%
3 months (2021-10-19) 35.72%
6 months (2021-07-19) 12.07%
1 year (2021-01-19) -21.89%
2 years (2020-01-17) -34.94%
3 years (2019-01-18) 27.03
5 years (2017-01-19) 1.23%

Heron Therapeutics financials

Revenue TTM $86.3 million
Gross profit TTM $-120,884,000
Return on assets TTM -37.04%
Return on equity TTM -115.32%
Profit margin -264.58%
Book value $1.17
Market capitalisation $886.8 million

TTM: trailing 12 months

Heron Therapeutics share dividends

We're not expecting Heron Therapeutics to pay a dividend over the next 12 months.

Have Heron Therapeutics's shares ever split?

Heron Therapeutics's shares were split on a 1:20 basis on 13 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeutics shares which in turn could have impacted Heron Therapeutics's share price.

Heron Therapeutics share price volatility

Over the last 12 months, Heron Therapeutics's shares have ranged in value from as little as $8.09 up to $20.45. A popular way to gauge a stock's volatility is its "beta".

HRTX.US volatility(beta: 1.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeutics's is 1.3401. This would suggest that Heron Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Heron Therapeutics overview

Heron Therapeutics, Inc. , a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A. P.

Stocks similar to Heron Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site